Evidence review demonstrates broad utility of universal germline testing in prostate cancer, highlighting benefits for targeted therapy, secondary cancer prevention, and cascade family testing.
Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become the standard of care for many cancers such as breast, ovarian, colorectal, pancreatic, and metastatic prostate cancer, and it is imperative that patients be offered timely and equitable access to testing as it can inform patient-physician shared decision making for management of the current cancer as well as anticipatory guidance for disease progression. Additionally, GGT guides screening for and prevention of secondary malignancies for the patient and cascade testing for at-risk family members. Here, we present data supporting the notion that clinicians should offer all patients with prostate cancer the opportunity to undergo comprehensive GGT for pathogenic germline variants known to be associated with familial cancer and/or known to have implications for treatment and management.
No takes yet. Share an insight, caveat, or question.
Shore et al. (2024) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: